VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CCELCryo-Cell International, Inc.
$3.17$26M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCCELFinancials

Cryo-Cell International, Inc. (CCEL) Financials

30Y historyFree accessUpdated daily

Revenue growth has trended into negative territory with a 3.6% year-over-year decline in 2026Q1, despite the company maintaining a robust gross margin profile of 78.4%.

CCEL Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMNov'25Nov'24Nov'23Nov'22Nov'21Nov'20Nov'19Nov'18Nov'17Nov'16Nov'15Nov'14Nov'13Nov'12Nov'11Nov'10Nov'09Nov'08Nov'07Nov'06Nov'05Nov'04Nov'03Nov'02Nov'01Nov'00Nov'99Nov'98Nov'97Nov'96
Sales/Revenue31.28M31.57M31.99M31.34M30.34M28.88M31.15M31.82M29.22M25.38M23.13M21.09M20.13M18.99M17.97M17.92M17.64M16.33M17.28M17.46M17.18M14.45M12.21M7.55M7.07M5.65M2.11M1.7M300K400K2.7M
Revenue Growth %-2.56%-1.31%2.05%3.32%5.03%-7.26%-2.1%8.89%15.1%9.76%9.66%4.79%5.96%5.7%0.29%1.58%8.04%-5.51%-1.04%1.63%18.88%18.35%61.74%6.74%25.22%167.78%24.08%466.67%-25%-85.19%-
Cost of Goods Sold7.05M7.38M7.95M8.44M8.79M8.99M9.66M10.04M8.54M6.72M5.77M5.63M5.63M5.32M4.89M4.4M4.5M4.53M6.11M6.59M6.07M4.14M3.16M2.63M2.5M1.66M827.33K200K200K0300K
COGS % of Revenue-23.37%24.85%26.93%28.98%31.12%31.01%31.54%29.23%26.49%24.97%26.7%27.98%28.02%27.2%24.55%25.54%27.76%35.38%37.76%35.32%28.67%25.9%34.77%35.28%29.32%39.22%11.76%66.67%-11.11%
Gross Profit24.23M24.19M24.04M22.9M21.54M19.9M21.49M21.78M20.68M18.66M17.35M15.46M14.49M13.67M13.08M13.52M13.13M11.79M11.16M10.87M11.11M10.31M9.05M4.92M4.58M3.99M1.28M1.5M100K400K2.4M
Gross Margin %77.47%76.63%75.15%73.07%71.02%68.88%68.99%68.46%70.77%73.51%75.03%73.3%72.02%71.98%72.8%75.45%74.46%72.24%64.62%62.24%64.68%71.33%74.1%65.23%64.72%70.68%60.78%88.24%33.33%100%88.89%
Gross Profit Growth %-0.63%4.96%6.3%8.29%-7.42%-1.33%5.33%10.82%7.53%12.24%6.67%6.01%4.52%-3.24%2.93%11.37%5.64%2.73%-2.2%7.8%13.94%83.72%7.57%14.67%211.42%-14.53%1400%-75%-83.33%-
Operating Expenses24.04M19.35M20.56M35.21M17.52M15.88M13.83M16.72M15.49M13.65M16.92M12.53M12.51M11.97M14.79M13.8M9.91M10.12M11.49M15.54M14.07M9.08M5.87M12.45M10.12M4.48M3.44M2.5M2.5M2.1M1.6M
OpEx % of Revenue-61.29%64.27%112.32%57.75%54.97%44.4%52.54%53.01%53.79%73.16%59.4%62.17%63.02%82.32%76.99%56.19%62%66.51%89.01%81.91%62.86%48.06%164.87%143.01%79.28%163.23%147.06%833.33%525%59.26%
Selling, General & Admin18.59M18.22M18.52M17.12M15.58M14.63M14.29M14.89M15.63M13.48M14.72M12.39M12.25M11.37M14.43M12.41M9.49M8.94M10.83M14.46M12.96M9.1M6.27M9.71M6.06M3.95M2.85M2.3M1.9M1.8M1.5M
SG&A % of Revenue-57.72%57.9%54.61%51.36%50.63%45.89%46.8%53.5%53.11%63.66%58.74%60.87%59.84%80.28%69.28%53.77%54.74%62.67%82.83%75.42%63%51.38%128.65%85.62%69.94%135.29%135.29%633.33%450%55.56%
Research & Development343.88K376.26K1.24M1.17M384.79K49.87K23.85K30.14K91.84K41.16K53.1K45.78K64.37K36.17K109.64K184.05K132.99K102.41K194.46K545.49K486.16K26.15K82.51K226.68K219.66K51.07K275.8K100K400K200K0
R&D % of Revenue-1.19%3.88%3.74%1.27%0.17%0.08%0.09%0.31%0.16%0.23%0.22%0.32%0.19%0.61%1.03%0.75%0.63%1.13%3.12%2.83%0.18%0.68%3%3.11%0.9%13.08%5.88%133.33%50%-
Other Operating Expenses1.56M751.47K794.32K16.92M1.55M1.22M-489.53K1.8M-235.02K131.61K2.14M92.11K196.98K566.97K256.69K1.2M294.06K1.08M469.5K532.31K629.15K-45.87K-488.89K2.51M3.84M476.48K313.49K100K200K100K100K
Operating Income191.52K4.84M3.48M-12.3M4.02M4.02M7.66M5.06M5.19M5.01M433.59K2.93M1.98M1.7M-1.71M-276.74K3.22M1.67M-326.75K-4.67M-2.96M1.22M3.18M-7.52M-5.54M-485.89K-2.16M-1M-2.4M-1.7M800K
Operating Margin %0.61%15.34%10.88%-39.26%13.27%13.91%24.6%15.91%17.76%19.72%1.87%13.91%9.84%8.96%-9.52%-1.54%18.27%10.24%-1.89%-26.76%-17.23%8.47%26.04%-99.64%-78.28%-8.6%-102.45%-58.82%-800%-425%29.63%
Operating Income Growth %-39.1%128.29%-405.73%0.16%-47.55%51.33%-2.44%3.66%1054.59%-85.22%48.05%16.35%199.51%-518.31%-108.59%92.69%611.79%93.01%-57.86%-341.84%-61.51%142.27%-35.86%-1039.57%77.52%-116.11%58.33%-41.18%-312.5%-
EBITDA1.55M6.21M3.96M-10.59M5.83M5.34M8.3M5.46M5.51M5.24M720.24K3.17M2.36M2.1M-1.24M303.11K3.8M2.34M351.4K-3.93M-2.24M1.82M3.84M-7.07M-4.73M26.74K-1.85M-900K-2.2M-1.6M900K
EBITDA Margin %4.95%19.67%12.39%-33.8%19.23%18.5%26.64%17.17%18.85%20.63%3.11%15.05%11.72%11.04%-6.92%1.69%21.56%14.36%2.03%-22.51%-13.01%12.6%31.42%-93.65%-66.94%0.47%-87.59%-52.94%-733.33%-400%33.33%
EBITDA Growth %-68.52%56.65%137.42%-281.59%9.15%-35.59%51.86%-0.77%5.16%627.01%-77.31%34.61%12.44%268.54%-510.55%-92.03%62.22%567.06%108.94%-75.84%-222.74%-52.53%154.27%-49.33%-17806.71%101.45%-105.28%59.09%-37.5%-277.78%-
D&A (Non-Cash Add-back)1.36M1.37M483.52K1.71M1.81M1.33M635.98K401.31K317.33K230K286.65K241.21K377.01K394.5K466.74K579.85K580.19K671.82K678.15K741.77K724.52K597.37K657.38K452.58K802.45K512.63K313.49K100K200K100K100K
EBIT-766.56K-270.9K939.44K-12.13M4.84M3.99M6.58M5.09M5.16M4.93M-1.53M2.25M1.83M1.6M-3.4M-466.85K3.37M2.96M700.7K-4.67M-2.96M1.22M3.18M-6.78M-5.96M-485.89K-2.16M-1M-2.2M-1.5M800K
Net Interest Income-2.03M-2.07M-1.86M-1.24M-1.52M-1.38M-1.54M-1.7M-1.55M-1.3M-947.34K-1.3M-1.15M-1.4M-1.02M-1.46M-1.26M-1.34M-1.17M-1.07M-693.02K-720.22K-702.62K-602.49K69.42K100.28K119.62K0-100K00
Interest Income000000000000000026.3K71.64K154.82K318.01K322.37K143.5K47.51K53.24K128.27K110.77K121.83K0000
Interest Expense2.03M2.07M1.86M1.24M1.52M1.38M1.54M1.7M1.55M1.3M947.34K1.3M1.15M1.4M1.02M1.46M1.28M1.42M1.32M1.39M1.02M863.71K750.13K655.73K58.85K10.48K2.21K0100K00
Other Income/Expense-2.99M-7.18M-676.16K-1.06M-705.52K-1.41M-2.62M-1.67M-1.57M-1.38M-2.91M-1.98M00-2.71M-1.42M-1.26M-12.97K-269.34K-332.75K232.98K-106.79K-160.71K1.07K209.56K485.89K2.16M1M2.2M100K-800K
Pretax Income-2.8M-2.34M2.8M-13.36M3.32M2.61M5.04M3.39M3.62M3.62M-2.48M949.52K677.15K197.02K-4.42M-1.7M1.78M1.55M-760.42K-5.01M-2.73M1.12M3.02M-7.52M-5.17M775.95K-1.61M-500K0-1.6M700K
Pretax Margin %-8.95%-7.4%8.77%-42.64%10.94%9.04%16.18%10.66%12.38%14.28%-10.72%4.5%3.36%1.04%-24.6%-9.47%10.09%9.47%-4.4%-28.67%-15.87%7.73%24.72%-99.62%-73.04%13.74%-76.34%-29.41%--400%25.93%
Income Tax-135.43K92.23K2.4M-3.84M547.54K527.71K1.41M1.1M4.47M1.31M-1.16M-7.16M123.53K169.58K1.89M171.94K-1.63M121.81K494.41K0-148.7K-36K86K1.1K161.5K-1.39M-670.37K-400K-100K0200K
Effective Tax Rate %4.84%-3.95%85.66%28.75%16.5%20.21%28.07%32.45%123.63%36.11%46.75%-753.73%18.24%86.07%-42.72%-10.13%-91.54%7.88%-65.02%0%5.45%-3.22%2.85%-0.01%-3.13%-178.56%41.63%80%-0%28.57%
Net Income-2.67M-2.43M402.1K-9.52M2.77M2.08M3.62M2.29M-854.82K2.32M-1.32M8.11M553.62K27.44K-6.31M-2.1M3.41M1.42M-760.42K-5.01M-2.81M1.03M2.84M-7.52M-5.33M899.63K-1.49M-600K-2.3M-1.6M600K
Net Margin %-8.52%-7.7%1.26%-30.38%9.14%7.21%11.64%7.2%-2.93%9.12%-5.71%38.43%2.75%0.14%-35.11%-11.69%19.34%8.73%-4.4%-28.67%-16.36%7.15%23.26%-99.63%-75.32%15.93%-70.67%-35.29%-766.67%-400%22.22%
Net Income Growth %-2170.66%-704.18%104.22%-443.57%33.02%-42.52%58.23%367.98%-136.92%275.28%-116.29%1364.24%1917.87%100.43%-201.04%-161.44%139.39%287.36%84.81%-78.04%-372.05%-63.62%137.76%-41.19%-692.18%160.35%-148.45%73.91%-43.75%-366.67%-
Net Income (Continuing)-2.67M-2.43M402.1K-9.52M2.77M2.08M3.62M2.29M-854.82K2.32M-1.32M8.11M553.62K27.44K-6.31M-2.1M3.46M1.42M-456.74K-5.01M-2.81M1.03M2.93M-6.83M-6.05M899.63K-1.49M-600K-2.3M-1.6M600K
Discontinued Operations0000000000000000000000000000000
Minority Interest000000000000000000000000298.39K000000
EPS (Diluted)-0.33-0.300.05-1.140.330.250.450.27-0.110.30-0.160.830.050.00-0.56-0.180.290.12-0.06-0.43-0.240.080.24-0.66-0.470.09-0.15-0.07-0.32-0.230.09
EPS Growth %-3300%-700%104.39%-445.45%32%-44.44%66.67%345.45%-136.67%287.5%-119.28%1560%-100.45%-211.11%-162.07%141.67%284.9%84.91%-79.17%-400%-66.67%136.36%-40.43%-622.22%160%-105.2%77.16%-39.13%-355.56%-
EPS (Basic)--0.300.05-1.140.330.260.480.29-0.110.33-0.160.850.050.00-0.56-0.180.290.12-0.06-0.43-0.240.090.25-0.66-0.470.09-0.15-0.07-0.32-0.230.09
Diluted Shares Outstanding8.06M8.07M8.21M8.34M8.48M8.36M8.14M8.41M7.46M7.65M8.11M9.8M10.43M10.97M11.31M11.76M11.81M11.8M11.73M11.66M11.62M12.23M11.91M11.35M11.34M10.58M9.76M8.21M7.28M6.96M7.18M
Basic Shares Outstanding8.06M8.07M8.13M8.34M8.47M8.14M8.14M8.41M7.46M7.06M8.11M9.54M10.18M10.86M11.31M11.76M11.75M11.75M11.73M11.66M11.62M11.58M11.37M11.35M11.34M10.58M9.76M8.21M7.28M6.96M7.18M
Dividend Payout Ratio--502.5%-276.85%--------------------------

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and enrollment stagnation

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Stagnation Amid Enrollment Headwinds

According to the latest quarterly financial disclosures, CCEL's revenue growth has trended into negative territory, with the most recent period showing a 3.6% year-over-year decline, suggesting that the company's core customer acquisition engine is struggling to maintain momentum in a competitive and discretionary healthcare market.

The consistent deceleration from positive growth in early 2024 to current contraction indicates that the company is failing to offset churn with new enrollments. This trend suggests that the firm's reliance on birth-rate-sensitive demand is becoming a structural liability rather than a stable annuity base.

Resilient Gross Margins Mask Volatility

As reported in recent income statements, CCEL maintains a robust gross margin profile averaging approximately 76%, which highlights the inherent scalability of its cryogenic storage infrastructure despite the broader operational challenges currently impacting the company's bottom-line profitability and overall financial health.

While the gross margin remains high, the significant gap between these figures and the erratic operating margins suggests that the company is struggling to control its overhead costs. Investors should monitor whether these high gross margins can be sustained if competitive pricing pressures force a reduction in service fees.

Operating Leverage Constrained by SG&A

Based on the provided financial data, CCEL's operating leverage appears severely compromised, as SG&A expenses frequently fluctuate in a manner that disproportionately impacts operating income, leading to inconsistent profitability and a reliance on non-operating items to stabilize the company's quarterly net income results.

The inability to consistently scale operating income alongside gross profit suggests that the company's administrative and marketing expenses are not optimized for its current revenue level. This lack of operating leverage may indicate that the firm is overspending on customer acquisition relative to the lifetime value of the contracts secured.

Expense Discipline Lacks Consistent Execution

Analysis of the company's cost structure reveals that SG&A remains the primary driver of earnings volatility, with quarterly expenditures often exceeding $5 million, which significantly outweighs the company's ability to generate consistent operating income from its core storage and processing service revenue streams.

The erratic nature of SG&A spending suggests a lack of rigorous expense discipline, which is particularly concerning given the company's thin cash position. Management appears to be struggling to balance the necessary investment in clinical partnerships with the need to maintain a lean operational footprint.

Liquidity Risks Threaten Strategic Pivot

Data from recent filings indicates that CCEL's cash reserves have dwindled to approximately $319,031, a precarious level that may force management to seek dilutive financing or debt to sustain its ongoing clinical-stage investments and daily operations in the face of persistent revenue contraction.

Short-sellers would likely focus on this liquidity crunch as a primary catalyst for future equity dilution. The company's pivot toward clinical-stage development appears increasingly risky when the core business is unable to generate sufficient free cash flow to fund its own strategic ambitions.

CCEL — Frequently Asked Questions

Quick answers to the most common questions about buying CCEL stock.

What was Cryo-Cell International, Inc.'s (CCEL) revenue in 2025?

For fiscal year 2025, Cryo-Cell International, Inc. (CCEL) reported total revenue of $31.6M. This represents a 1069.1% increase compared to $2.7M in 1996.

Is Cryo-Cell International, Inc. (CCEL) profitable?

Cryo-Cell International, Inc. (CCEL) reported a net loss of $2.4M for the fiscal year ending 2025.

What is Cryo-Cell International, Inc.'s operating profit margin?

Cryo-Cell International, Inc. (CCEL) reported an operating income of $4.8M, resulting in an operating profit margin of 15.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Cryo-Cell International, Inc.'s gross profit and gross margin?

Cryo-Cell International, Inc. (CCEL) generated $24.2M in gross profit for the year, representing a gross profit margin of 76.6%. This demonstrates the company's core pricing power and production efficiency.